The development of immunotherapies, particularly antibodies that inhibit the PD-1/PD-L1 pathways, has revolutionized the treatment of patients worldwide with advanced or metastatic NSCLC and improved their survival outcomes (104). The gene discussed is CD274; the disease is non-small cell lung carcinoma.